Contribute Try STAT+ Today

Key negotiations that helped seal Gilead Science’s $21 billion purchase of Immunomedics, announced Sunday, took place on the makeshift patio of a suburban New Jersey restaurant during a socially distanced dinner two weeks ago, separated from a highway by some hedges.

Immunomedics’ Executive Chairman Behzad Aghazadeh, eating at a restaurant for the first time since the Covid-19 pandemic struck, ordered lamb chops. Gilead CEO Daniel O’Day had steak. They requested a table away from other diners in order to be discreet. But the main thing on the menu, from Gilead’s perspective, was Trodelvy, Immunomedics’ recently approved drug to treat women with triple-negative breast cancer, a particularly aggressive form of the disease with few treatment options. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Can someone find out ASAP what is Behzad’s severance psckage then share it publicly? I am sure it would be transformative for his personal wealth!

    • John, the transformation won’t come in the form of a severance package. It will come in Behzad’s 20% carry on Avoro’s huge profits in IMMU. That is his leverage.

  • Hey Mr. Lawman,

    I thought Dan is the new management after Martin and Milligan? You think he is doing much better? Seriously?

  • So Trodelvy would be destined or would turn outvsimilarly for Gilead as Opdivo and Yervoy for Bristol Myers Squib and Keytruda for Merck? Who is drinking this preposterous Kool Aid? Not I!

  • “You cannot under-appreciate how the people behind a drug will impact its successful advancement.”

    This comment seems to apply to Cytodyn that has a great drug in Leronlimab, but, in my opinion, could fare better with new management.

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy